Evolva announces change in management team
Neil Goldsmith, CEO and Managing Director of Evolva Holding SA commented, "Melya has been an integral part of the management team over the past five years. On behalf of the Board and the Evolva team, we extend our gratitude to Melya for her contributions and wish her the best in her future endeavours."
Mr. Murali has over 20 years experience in pharmaceutical and healthcare R&D. He has led Evolva's Indian operations since September 2006 and is a member of the Group Management Team of Evolva Holding SA.
About Evolva Holding SA
Evolva's proprietary discovery technology platform uses a "disruptive" technological approach to the creation of novel small compounds that differs sharply from the prevailing synthetic chemistry and protein engineering approaches in the pharmaceutical industry today. Based on this technology, Evolva has a number of discovery and preclinical partnerships which in 2009 generated revenues of CHF 18.9 million. Evolva also has an attractive pipeline of compounds - one drug candidate (for renal and cardiovascular diseases) entered Phase I at the beginning of 2009, and two others (an antifungal and an antiviral) are in late preclinical stages. Evolva is listed in the main standard of the SIX Swiss Exchange with the ticker EVE. For more information see www.evolva.com.